Company intelligence / Profile preview
OMass Therapeutics
Oxford, England, United Kingdomomass.com ↗
- Ownership
- Private
- Employees
- ~57
- Development stage
- Other
01
Overview
Lead program is an insurmountable antagonist of the GPCR MC2 receptor for Congenital Adrenal Hyperplasia, expected to complete IND-enabling studies in 2025. The company has made significant progress with its portfolio of highly-validated, yet intractable or inadequately drugged targets.
- Therapeutic areas
- GastroenterologyEndocrinologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on OMass Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMass Therapeutics.